A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Inclusion Criteria

• Age: Patients must be > 12 months and 50% for patients >16 years of age and Lansky > 50 for children 8 weeks.

Exclusion Criteria

• Patients who have received bevacizumab and/or Irinotecan previously are ineligible. Non brain tumor patients who have previously received Temozolomide are ineligible.
• Pregnancy or Breast-Feeding: Pregnant patients are ineligible for this study due to the known teratogenic effects of the cytotoxic agents. Pregnancy tests must be obtained in females of childbearing potential prior to enrollment.
• Lactating women must agree not to breast-feed.
• Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.
• Patients Who Have an Uncontrolled Infection will not be eligible for enrollment until all infections are under control.
• Clinically Significant Unrelated Systemic Illness: Patients with serious infections or significant pulmonary, hepatic, renal, or other end-organ dysfunction which in the judgment of the Principal or Co-Investigators would compromise the patient's ability to tolerate prescribed chemotherapy or are likely to interfere with the study procedures or results will not be eligible.